EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Inhibition of Retinal Neovascularization by BEZ235: Targeting the Akt/4EBP1/Cyclin D1 Pathway in Endothelial Cells

Qi Liu, Ling-Xiao Xia, Wan-Zhao Yi, Ya-Ni Wu, Shuo-Shuo Gu, Jian-Ying Chen, Ting-Ting Liu, Ying-Hui Lu, Yu-Hong Cui, Jing Meng, Hong-Wei Pan

Investigative Ophthalmology & Visual Science · 2025

DOI: 10.1167/iovs.66.1.66 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Qi Liu and 10 co-authors. Institution: Institute of Ophthalmology, School of Medicine, Jinan University, Guangzhou, China. Major MEDLINE topics: Cyclin D1, Retinal Neovascularization, Quinolines, Adaptor Proteins, Signal Transducing. Cited 3 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

To investigate the therapeutic efficacy of BEZ235, a dual PI3K/mTOR inhibitor, in suppressing pathological neovascularization in an oxygen-induced retinopathy (OIR) mouse model and explore the role of cyclin D1 in endothelial cell cycle regulation.

Methods

Single-cell RNA sequencing was performed to analyze gene expression and cell-cycle alterations in retinal endothelial cells under normoxic and OIR conditions. The effects of BEZ235 on human umbilical vein endothelial cells (HUVECs) and human retinal microvascular endothelial cells (HRMECs) were evaluated by assessing cell viability, cell-cycle progression, proliferation, migration, and tube formation. In the OIR mouse model, retinal neovascularization was evaluated by retinal flatmount immunofluorescence staining, hematoxylin and eosin (H&E) staining, quantitative reverse-transcription polymerase chain reaction (RT-qPCR), and western blot analyses. The in vivo toxicity of BEZ235 was evaluated by electroretinography (ERG) and histological examination of the heart, liver, spleen, lungs, and kidneys.

Results

In vitro, BEZ235 significantly inhibited cell cycle progression by downregulating cyclin D1 at both mRNA and protein levels, inducing G0/G1 phase arrest. This led to significant reductions in cell viability, proliferation, migration, and tube formation. In the OIR model, BEZ235 substantially decreased neovascularization and improved vascular organization. BEZ235 mediates its effects by inhibiting the PI3K/Akt/mTOR pathway, reducing Akt and 4E-binding protein 1 (4EBP1) phosphorylation levels, thus downregulating cyclin D1 expression. ERG and histological examination suggested that BEZ235 did not induce evident retinal or systemic toxicity at the dosage used to inhibit retinal neovascularization.

Conclusions

BEZ235 effectively inhibits retinal neovascularization by downregulating cyclin D1 via 4EBP1 phosphorylation inhibition, highlighting its potential as a promising therapeutic agent for retinal neovascularization diseases.

Subjects

MeSH terms (MEDLINE)

Cyclin D1Retinal NeovascularizationQuinolinesAdaptor Proteins, Signal TransducingImidazolesProto-Oncogene Proteins c-aktAnimalsMiceHumansDisease Models, AnimalCell ProliferationCell Cycle ProteinsHuman Umbilical Vein Endothelial CellsMice, Inbred C57BLSignal TransductionBlotting, WesternCells, CulturedCell MovementCell Survival

Substances

Cyclin D1dactolisibQuinolinesAdaptor Proteins, Signal TransducingImidazolesProto-Oncogene Proteins c-aktCell Cycle ProteinsEIF4EBP1 protein, humanEif4ebp1 protein, mouse

Authors and institutions

  • Institute of Ophthalmology, School of Medicine, Jinan University, Guangzhou, China.
  • Department of Ophthalmology, the First Affiliated Hospital, Jinan University, Guangzhou, China.
  • Department of Cardiology, Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Department of Histology and Embryology, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.
  • The Affiliated Shunde Hospital of Jinan University, Foshan, China.

Cite

APA

Liu, Q., Xia, L. X., Yi, W. Z., Wu, Y. N., Gu, S. S., Chen, J. Y., Liu, T. T., Lu, Y. H., Cui, Y. H., Meng, J., & Pan, H. W. (2025). Inhibition of Retinal Neovascularization by BEZ235: Targeting the Akt/4EBP1/Cyclin D1 Pathway in Endothelial Cells. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.1.66

Vancouver

Liu Q, Xia LX, Yi WZ, Wu YN, Gu SS, Chen JY, et al. Inhibition of Retinal Neovascularization by BEZ235: Targeting the Akt/4EBP1/Cyclin D1 Pathway in Endothelial Cells. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.1.66

BibTeX
@article{Liu2025,
  author = {Liu, Qi and Xia, Ling-Xiao and Yi, Wan-Zhao and Wu, Ya-Ni and Gu, Shuo-Shuo and Chen, Jian-Ying and Liu, Ting-Ting and Lu, Ying-Hui and Cui, Yu-Hong and Meng, Jing and Pan, Hong-Wei},
  title = {Inhibition of Retinal Neovascularization by BEZ235: Targeting the Akt/4EBP1/Cyclin D1 Pathway in Endothelial Cells},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2025},
  doi = {10.1167/iovs.66.1.66}
}
Start for free →